Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients

被引：0
|
作者：
He Huang
Ming-Long Cai
Xiao-Jie Hong
Li-Jun Zheng
Zhu-Lin Hu
Tao Yuan
Wei-Ran Li
Yu-Jun Sheng
Xue-Jun Zhang
机构：
[1] the First Affiliated Hospital of Anhui Medical University,Department of Dermatology
[2] Anhui Medical University,Institute of Dermatology
[3] Anhui Medical University,Key Laboratory of Dermatology
[4] Ministry of Education,State Key Laboratory Incubation Base of Dermatology
[5] Anhui Medical University,undefined
[6] Key Laboratory of Major Autoimmune Diseases,undefined
来源：
European Journal of Dermatology | 2020年 / 30卷
关键词：
psoriasis; secukinumab; efficacy; safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：554 / 560
页数：6
相关论文
共 50 条
  • [41] Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study
    Galica, Katarzyna
    Lesiak, Aleksandra
    Ciazynska, Magdalena
    Noweta, Marcin
    Bednarski, Igor
    Narbutt, Joanna
    [J]. POSTEPY DERMATOLOGII I ALERGOLOGII, 2021, 38 (06): : 973 - 978
  • [42] Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab
    Malakouti, Mona
    Jacob, Sharon E.
    Anderson, Nancy J.
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2016, 9 : 347 - 355
  • [43] REAL-WORLD EFFECTIVENESS OF DUPILUMAB ON ORAL CORTICOSTEROID USE IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA
    Pawar, A.
    Blaiss, M.
    Modena, B.
    Khan, A.
    DePrado-Gomez, L.
    Pandit-Abid, N.
    Radwan, A.
    Jacob-Nara, J.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S48 - S49
  • [44] A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
    Emily K. Haque
    Aaminah Azhar
    John Corbett
    Jillian Frieder
    Xuan Wang
    Alan Menter
    [J]. Dermatology and Therapy, 2020, 10 : 1121 - 1135
  • [45] A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
    Haque, Emily K.
    Azhar, Aaminah
    Corbett, John
    Frieder, Jillian
    Wang, Xuan
    Menter, Alan
    [J]. DERMATOLOGY AND THERAPY, 2020, 10 (05) : 1121 - 1135
  • [46] Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
    Torres, Tiago
    Varela, Paulo
    Bastos, Pedro Mendes
    Magina, Sofia
    Henrique, Martinha
    Ferreira, Paulo
    [J]. DRUGS IN CONTEXT, 2024, 13
  • [47] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
    Augustin, Matthias
    Sommer, Raquel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [48] REAL-WORLD EFFECTIVENESS AND SAFETY IN A PHASE 4 STUDY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Bhatia, N.
    Vasquez, J. G.
    Schenkel, B.
    Rozzo, S. J.
    Heim, J.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S57 - S57
  • [49] Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
    Galluzzo, Marco
    Talamonti, Marina
    Bernardini, Nicoletta
    Chiricozzi, Andrea
    De Simone, Clara
    Bonifati, Claudio
    Bruni, Pierluigi
    Diotallevi, Federico
    Esposito, Maria
    Graceffa, Dario
    Hansel, Katharina
    Loconsole, Francesco
    Moretta, Gaia
    Mugheddu, Cristina
    Papini, Manuela
    Richetta, Antonio
    Skroza, Nevena
    Atzori, Laura
    Fargnoli, Maria Concetta
    Persechino, Severino
    Offidani, Annamaria
    Stingeni, Luca
    Peris, Ketty
    Potenza, Concetta
    Bianchi, Luca
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1585 - 1592
  • [50] Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events
    Gulliver, Wayne
    Penney, Michelle
    Power, Rebecca
    Gulliver, Susanne
    Montmayeur, Sonia
    Burge, Russel
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 354 - 360
12345